Shows
Yale Cancer Answers2025 ASCO Annual Meeting Highlights2025 ASCO Annual Meeting Highlights with guest Dr. Ian Krop June 8, 2025 Yale Cancer Center visit: http://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095 2025-06-0829 min
Research To Practice | Oncology VideosBreast Cancer: Additional Perspectives — Year in Review Series on Relevant New Datasets and AdvancesFeaturing perspectives from Dr Ian E Krop and Dr Sara M Tolaney, including the following topics: Introduction: Adjuvant CDK4/6 Inhibition (0:00) HER2-Positive Disease (11:13) PARP Inhibition (27:34) Antibody-Drug Conjugates (34:12) Up-Front Treatment of HR-Positive Metastatic Disease (46:28) CME information and select publications2025-06-041h 01
Breast Cancer UpdateBreast Cancer: Additional Perspectives — Year in Review Series on Relevant New Datasets and AdvancesDr Ian Krop from Yale Cancer Center in New Haven, Connecticut, and Dr Sara Tolaney from Dana-Farber Cancer Institute in Boston, Massachusetts, summarize major treatment advances over the past year and review relevant ongoing clinical trials for patients with breast cancer. CME information and select publications here. 2025-06-041h 01
Oncology Today with Dr Neil LoveBreast Cancer: Additional Perspectives — Year in Review Series on Relevant New Datasets and AdvancesDr Ian Krop from Yale Cancer Center in New Haven, Connecticut, and Dr Sara Tolaney from Dana-Farber Cancer Institute in Boston, Massachusetts, summarize major treatment advances over the past year and review relevant ongoing clinical trials for patients with breast cancer. CME information and select publications here. 2025-06-041h 01Yale Cancer AnswersIncreasing Access to Clinical TrialsIncreasing Access to Clinical Trials with guests Dr. Ian Krop and Alyssa Gateman, January 12, 2025 Yale Cancer Center visit: http://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-40952025-01-1229 min
Research To Practice | Oncology VideosMetastatic Breast Cancer | Rounds with the Investigators: Compelling Teaching Cases Focused on the Management of Metastatic Breast CancerFeaturing perspectives from Dr Erika Hamilton, Dr Kevin Kalinsky, Dr Ian E Krop, Dr Joyce O’Shaughnessy and Dr Sara M Tolaney, including the following topics: Introduction (0:00) Optimizing the Care of Patients with HER2-Positive Metastatic Breast Cancer (mBC) — Dr Krop (10:17) Selection and Sequencing of Therapy for Patients with Metastatic Triple-Negative Breast Cancer — Dr Tolaney (37:54) Integrating Novel Agents and Approaches into the Management of Endocrine-Resistant Hormone Receptor-Positive mBC — Dr Kalinsky (53:59) Tolerability Considerations with Approved and Investigational Antibody-Drug Conjugates — Dr O’Shaughnessy (1:14:16) Other Important Care Considerations for Patients with mBC — Dr Hamilton (1:41:30) CME information and select publications2025-01-102h 01Breast Cancer UpdateMetastatic Breast Cancer — San Antonio 2024 symposium series proceedings Part 3Dr Erika Hamilton from the Sarah Cannon Research Institute in Nashville, Tennessee, Dr Kevin Kalinsky from the Winship Cancer Institute of Emory University in Atlanta, Georgia, Dr Ian E Krop from the Yale Cancer Center in New Haven, Connecticut, Dr Joyce O’Shaughnessy from the Sarah Cannon Research Institute in Dallas, Texas, and Dr Sara M Tolaney from the Dana-Farber Cancer Institute in Boston, Massachusetts, discuss available and novel treatment strategies for metastatic breast cancer.2025-01-102h 01
Oncology Today with Dr Neil LoveMetastatic Breast Cancer — San Antonio 2024 symposium series proceedings Part 3Dr Erika Hamilton from the Sarah Cannon Research Institute in Nashville, Tennessee, Dr Kevin Kalinsky from the Winship Cancer Institute of Emory University in Atlanta, Georgia, Dr Ian E Krop from the Yale Cancer Center in New Haven, Connecticut, Dr Joyce O’Shaughnessy from the Sarah Cannon Research Institute in Dallas, Texas, and Dr Sara M Tolaney from the Dana-Farber Cancer Institute in Boston, Massachusetts, discuss available and novel treatment strategies for metastatic breast cancer, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here.2025-01-102h 01
Oncology News Central Peer-Spectives“Confusing for All of Us”: Questions Arise Over ADCs, HER2 in Metastatic Breast CancerApprovals of antibody-drug conjugates (ADCs) for metastatic breast cancer have introduced complex questions about HER2 expression. “It’s certainly been a changing landscape, which has been confusing for all of us,” explains Ian Krop, MD, PhD, director of the clinical trials office, chief clinical research officer, and associate director for clinical sciences at Yale Cancer Center in New Haven, Connecticut. He and Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai Cancer Center in Los Angeles, discuss how oncologists should best approach HER2 testing, ADC sequencing, and toxicity concerns. When it comes to answering key qu...2024-10-2114 minOncology News Central Peer-Spectives“Confusing for All of Us”: Questions Arise Over ADCs, HER2 in Metastatic Breast CancerApprovals of antibody-drug conjugates (ADCs) for metastatic breast cancer have introduced complex questions about HER2 expression. “It’s certainly been a changing landscape, which has been confusing for all of us,” explains Ian Krop, MD, PhD, director of the clinical trials office, chief clinical research officer, and associate director for clinical sciences at Yale Cancer Center in New Haven, Connecticut. He and Robert A. Figlin, MD, the Steven Spielberg Family Chair in Hematology-Oncology at the Cedars-Sinai Cancer Center in Los Angeles, discuss how oncologists should best approach HER2 testing, ADC sequencing, and toxicity concerns. When it comes to answering key qu...2024-10-2114 min
Research To Practice | Oncology VideosHER2-Positive and Triple-Negative Breast Cancer | Ian E Krop, MD, PhDYear in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in HER2-Positive and Triple-Negative Breast Cancer | Faculty Presentation 1: HER2-Positive Breast Cancer — Ian E Krop, MD, PhD CME information and select publications2024-03-1553 min
Research To Practice | Oncology VideosHER2-Positive and Triple-Negative Breast Cancer | Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in HER2-Positive and Triple-Negative Breast CancerFeaturing perspectives from Dr Ian E Krop and Dr Priyanka Sharma, including the following topics: Introduction: Educating Non-Breast Cancer Specialty Oncologists About HER2-Targeted Therapies – ASCO Genitourinary Cancers Symposium 2024 (0:00) HER2-Positive Breast Cancer — Dr Krop (12:30) Triple-Negative Breast Cancer — Dr Sharma (36:34) CME information and select publications 2024-03-151h 05
Oncology Today with Dr Neil LoveYear in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in HER2-Positive and Triple-Negative Breast Cancer
Dr Ian E Krop from the Yale Cancer Center in New Haven, Connecticut, and Dr Priyanka Sharma from the University of Kansas Cancer Center in Westwood, Kansas, discuss patient cases and treatment strategies for HER2-positive and triple-negative breast cancer, moderated by Dr Neil Love. Produced by Research To Practice.
CME information and select publications here.
2024-03-151h 05Breast Cancer UpdateYear in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in HER2-Positive and Triple-Negative Breast CancerDr Ian E Krop from the Yale Cancer Center in New Haven, Connecticut, and Dr Priyanka Sharma from the University of Kansas Cancer Center in Westwood, Kansas, discuss patient cases and treatment strategies for HER2-positive and triple-negative breast cancer.2024-03-151h 05
JCO Precision Oncology ConversationsJCO PO Article Insights: Prediction of Adjuvant Pertuzumab Benefit by 80-GSIn this JCO Precision Oncology Article Insights episode, Mitchell Elliot provides a summary on "Prediction of Benefit From Adjuvant Pertuzumab by 80-Gene Signature in the APHINITY (BIG 4-11) Trial," by Krop, et al published on January 18th, 2024. TRANSCRIPT Mitchell Elliott: Hello and welcome to JCO Precision Oncology Article Insights. I'm your host, Mitchell Elliott, an ASCO Journal Editorial Fellow. Today, I will be providing a summary of the article titled "Prediction of Benefit from Adjuvant Pertuzumab by 80-Gene Signature in the APHINITY (BIG 4-11) Trial" by Dr. Ian Krop on behalf of the APHINITY Steering...2024-02-2807 min
Research To Practice | Oncology VideosVideo Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Management of Breast CancerFeaturing perspectives from Dr Komal Jhaveri, Dr Kevin Kalinsky, Dr Ian E Krop, Dr Joyce O’Shaughnessy, Dr Hope S Rugo and Prof Peter Schmid, including the following topics: Long-Term Management of HER2-Positive Breast Cancer Introduction (0:00) Management of CNS-only disease progression in patients with HER2-positive metastatic breast cancer (2:27) Synergy between tucatinib and HER2-targeted antibody-drug conjugates (5:24) Management of trastuzumab deruxtecan–related adverse events (7:41) Patient selection for and practical implementation of postadjuvant neratinib (13:23) Faculty presentation: Dr Krop (16:26) Optimizing the Management of ER-Positive Localized Breast Cancer Ovarian function suppression to preserve fertility and prevent premature ovarian insufficiency; interrupting adju...2023-06-262h 30
Investigating Breast CancerBridging the Gap Between the Lab and Patient Care with Dr. Ian KropIn the latest episode of Investigating Breast Cancer, Dr. Ian Krop discusses his team’s work to advance clinical trials through—including one to test immunotherapy in HER2-positive breast cancer. A BCRF investigator since 2017, Dr. Krop is the chief clinical research officer and associate cancer center director for clinical research at the Yale Cancer Center.
Dr. Krop also currently serves as chief scientific officer for the BCRF-supported Translational Breast Cancer Research Consortium.
2023-04-2028 min
Research To Practice | Oncology VideosHER2-Positive Breast Cancer | What Clinicians Want to Know: Addressing Current Questions and Controversies in the Management of HER2-Positive Breast CancerFeaturing perspectives from Drs Erika Hamilton, Sara Hurvitz, Ian Krop, Shanu Modi and Sara Tolaney, including the following topics: Optimizing the Management of Localized HER2-Positive Breast Cancer Introduction (0:00) Case: A woman in her mid 60s with pulmonary hypertension and triple-positive, node-positive infiltrating ductal carcinoma (IDC) after neoadjuvant TCHP and clinical complete remission — Susmitha Apuri, MD (4:31) Case: A woman in her early 60s with a 1.7-cm, triple-positive, clinically node-negative IDC — Ranju Gupta, MD (10:05) Dr Tolaney presentation (18:44) Current Considerations in the Treatment of HER2-Positive Metastatic Breast Cancer (mBC) Case: A woman in her early 60s with an 8-cm, ER-ne...2022-12-222h 10
Research To Practice | Oncology VideosBreast Cancer | Proceedings from a Daylong Multitumor Educational Symposium in Partnership with Florida Cancer SpecialistsProceedings from a daylong symposium hosted in partnership with Florida Cancer Specialists, featuring key clinical presentations and papers in breast cancer. Featuring perspectives from Drs Matthew Goetz and Ian Krop, including the following topics: HER2-Positive and HER2-Low Disease (0:00) ER-Positive, HER2-Negative Disease (31:55) CME information and select publications2022-11-161h 01
Research To Practice | Oncology VideosBreast Cancer| Proceedings from a CME Hybrid Symposium Series Held in Conjunction with the 2022 ASCO Annual MeetingFeaturing perspectives from Drs Javier Cortés, Matthew Goetz, Erika Hamilton, Ian Krop, Hope Rugo and Sara Tolaney, including the following topics: Introduction (0:00) Optimizing the Management of ER-Positive Localized Breast Cancer — Matthew P Goetz, MD (7:50) New and Novel Treatment Strategies for Localized Triple-Negative Breast Cancer (TNBC) — Erika Hamilton, MD (38:35) Considerations in the Care of Patients with Localized HER2-Positive Breast Cancer — Ian E Krop, MD, PhD (56:03) Evolving Clinical Decision-Making for Patients with HER2-Positive Metastatic Breast Cancer (mBC) — Javier Cortés, MD, PhD (1:18:47) Selection and Sequencing of Therapy for ER-Positive, HER2-Negative mBC — Hope S Rugo, MD (1:40:41) Recent Advances in the...2022-06-282h 30
OnconewsctDNA, recorrência tardia e impacto dos estudos RxPONDER e monarchE no manejo cirúrgico da axilaOs resultados dos ensaios RxPONDER e monarchE informaram as recomendações de terapia sistêmica para câncer de mama RH+, HER2-negativo. Dada a importância da extensão da doença nodal nesses estudos, o manejo cirúrgico da axila ressurgiu como uma questão importante. Esses pacientes precisariam de uma maior dissecção de linfonodos axilares (ALND) para determinar a carga nodal total e informar as recomendações de terapia sistêmica? O assunto foi tema de artigo de opinião no Journal of Global Oncology (JCO) e está em pauta em mais um PODCAST ONCONEWS. Nessa edição, Si...2022-06-2421 min
Oncology Data AdvisorPatritumab Deruxtecan for HER3-Expressing Metastatic Breast Cancer: Ian Krop, MD, PhDThis playlist features episodes that were recorded live at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago by Oncology Data Advisor and ConveyMed. For more information, visit oncdata.com and conveymed.io, and don’t forget to follow us on social media for news, exclusive interviews, and more!2022-06-2008 min
Real PinkEpisode 117: HER2-positive Breast Cancer: What You Should KnowBreast cancer is not just one disease - there are many different types of breast cancer. HER2- positive breast cancer is one of the more common types, making up about 10-20 percent of newly diagnosed breast cancers. Today, we are talking to Dr. Ian Krop, Associate Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute & Associate Professor of Medicine at Harvard Medical School. Dr. Krop is a physician-scientist that treats patients and conducts clinical trial research in breast cancer. He is a leading expert on HER2-positive breast cancer and a Komen Scholar.Special Gu...2021-06-1413 min
The Lancet Oncology in conversation withThe Lancet Oncology: May 02, 2014Ian Krop discusses a phase III trial to assess efficacy of trastuzumab emtansine for women with recurrent HER2-positive breast cancer.Tell us what you thought about this episodeContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv2014-05-0209 min
Listen to The Lancet OncologyThe Lancet Oncology: May 02, 2014Ian Krop discusses a phase III trial to assess efficacy of trastuzumab emtansine for women with recurrent HER2-positive breast cancer.2014-05-0209 minListen to The Lancet OncologyThe Lancet Oncology: May 02, 2014Ian Krop discusses a phase III trial to assess efficacy of trastuzumab emtansine for women with recurrent HER2-positive breast cancer.2014-05-0209 min